Please login to the form below
genomes
This page shows the latest genomes news and features for those working in and with pharma, biotech and healthcare.
Horizon Discovery and C4X to harness CRISPR for new cancer drugs
Jon Moore. “Drugging the cancer genome now requires new synthetic lethal therapies that can exploit the vulnerabilities in patient's tumours that are created by mutations in undruggable cancer driver gene,”
Latest news
-
AZ and CRUK launch Cambridge genomics centre
genome. Scientists will also have access to CRISPR libraries for silencing or activating every gene in the genome, which follows on from an existing deal between AZ and the Wellcome Sanger ... The announcement was made just days after Genomics England
-
UK’s genomics leadership attracts IQVIA investment, regardless of Brexit
Genomics England has just hit its target of sequencing 100, 000 genomes, and this world-leading status, and the new IQVIA alliance, bring the vision of UK clinical research and NHS
-
Genomics England reaches 100,000th genome sequencing milestone
th. genome. First launched in 2012 under then Prime Minister David Cameron, the 100, 000 Genome Project had ambitious plans to map the genomes of NHS patients to deliver treatments for ... He said: “Sequencing the 100, 000th genome is a major
-
Grail to initiate largest ever UK cancer screening study
That initiative builds on the 100, 000 Genome Project, and data from that could soon be integrated into medical records, a move which could help the UK's NHS become a
-
Duchenne UK backs Evox dystrophin delivery project
One of the big problems facing gene therapies that the dystrophin gene is long – in fact the longest gene sequence in the human genome – so truncated versions coding for ‘microdystrophins’ have
More from news
Approximately 8 fully matching, plus 135 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
The agreement is for the development of therapies to eliminate the hepatits B virus (HBV) in vivo using the genome editing platform ARCUS. Development will be shared, with Precision responsible for
-
The critical role of science in healthcare communications
Entirely new fields of medicine are emerging, such as human genomics and precision therapies that are tailor-made for the individual based on specific genome sequencing.
-
Can new data aggregators shift the balance of power away from pharma?
However, it was only 20 years ago that several genomics companies, led by Human Genome Sciences Inc, thought they could secure a monopoly position over unprecedented drug targets by filing patents ... on gene sequences emerging from their own human
-
30 Women Leaders in UK Healthcare
100, 000 Genomes Project. ... It represents the world’s largest depository of whole genomes with associated clinical data, and is already being used to diagnose and personalise treatment for people with rare diseases and cancers.
-
Integrating digital biomarkers into precision medicine
In many ways, this model parallels traditional biomarker development where, for example, blood samples can be collected early in clinical research to then support genome-wide association studies to detect genetic
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Editas Medicine names James Mullen as chairman
He has previously served as CEO of Patheon. Genome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.
-
Editas Medicine adds to its board of directors
Jessica Hopfield will also serve on the genome editing firm's audit committee. ... Genome editing company Editas Medicine has strengthened its board of directors with the addition of Jessica Hopfield, who will also serve on the board's audit committee.
-
Former GSK CEO joins Synthego’s advisory board
I look forward to contributing to the company’s success as the business extends further into the genome engineering market.”. ... Andrew’s appointment strengthens the company’s position as a leader in genome engineering solutions.”.
-
Paul Stockdale joins Oxford BioDynamics as CFO
A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.
-
Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel
They will join the board of directors. Genome editing group Intellia Therapeutics has appointed Moncef Slaoui and Frank Verwiel to join its board of directors at a time when the board ... We look forward to their guidance as we continue to advance our
More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Life Science and Chemical Instrumentation Market to Register Steady Expansion During 2015 - 2025
Increased funding by governments and corporate sectors in research and development, advances in life science and research, emergence of proteomicsand innovations with human genome mapping has also increased the demand for
-
Life Science and Chemical Instruments Market: Industry Trends, Survey, Growth and Forecast to 2015-2025
Also, the emergence of proteomics and innovations in human genome mapping have also increased the demand for the instruments in research and development laboratories and academic institutions.
-
World AIDS Day 2018: Fighting the stigma surrounding HIV
10. Tenofovir – a nucleotide reverse transcriptase inhibitor (NtRTI). 11. Acts as a nucleotide analogue that competitively inhibits reverse transcriptase, the enzyme required for replication of the viral genome.
-
Artificial Intelligence in Healthcare
However, the robots received ‘points’ for finding the resource themselves and only the highest-scoring robots were ‘mated’; their binary code ‘genome’ forming part of the next generation of robots.
-
The dark side of direct-to-consumer genetic tests
The organisation works across 153 countries. Its services range from conducting government research to providing patients and healthcare professionals with diagnostic results, offering genome studies and using genomics in forensics. ... To date it has
More from PMHub
Approximately 2 fully matching, plus 15 partially matching documents found.
Featured jobs
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Business Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Director
-
Competitive Salary Offered
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Account Director, Medical Education
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
Subscribe to our email news alerts
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Novartis forges AI alliance with Oxford University
- FDA adcomm split on Sanofi’s type 1 diabetes drug
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Essential collaboration skills training for pharma and healthcare teams launched by Dovetail.
PMHub
Consulting at McCann Health
We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
